// STATE LEGISLATION TRACKER

Minnesota HF 4188 — Commerce policy bill.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Minnesota
Bill: HF 4188
Filed: 2026-03-12
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

HF4188 is labeled as a Minnesota commerce policy bill, and the available metadata does not show peptide-specific content. Based only on the title, subjects, and failed latest-action fetch, there is no clear impact on compounded peptides, off-label prescribing, telehealth care, clinician scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No visible peptide-specific provisions from the available metadata
No clear change to compounded peptide access or prescribing rules
No listed telehealth, NP, naturopathic, FDA compounding, or PDMP impact

What to Watch For

Note Watch for bill text or summaries that mention pharmacies, compounding, prescriptions, telehealth, or provider licensing.

Note A broad commerce bill could be amended later, but no peptide-relevant language is visible from the supplied metadata.

Note OpenStates did not provide a current latest action, so status should be rechecked before relying on it.

Where the Bill Stands

The source metadata says the latest action refetch failed, so the bill's current procedural status cannot be confirmed from the provided information.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws